Current state and next-generation CAR-T cells in multiple myeloma

Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma

(2021) Matteo C. Da Vià et al.   NATURE MEDICINE

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

(2021) Nikhil C. Munshi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma

(2021) Mehmet Kemal Samur et al.   Nature Communications

CXCR4 and anti-BCMA CAR co-modified natural killer cells suppress multiple myeloma progression in a xenograft mouse model

(2021) Yu Yang Ng et al.   CANCER GENE THERAPY

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

(2021) Jesus G Berdeja et al.   LANCET

The multiple myeloma microenvironment is defined by an inflammatory stromal cell landscape

(2021) Madelon M. E. de Jong et al.   NATURE IMMUNOLOGY

NKG2D-CAR-transduced natural killer cells efficiently target multiple myeloma

(2021) Alejandra Leivas et al.   Blood Cancer Journal

Effective anti-BCMA retreatment in multiple myeloma

(2021) Nicolas Gazeau et al.   Blood Advances

Universal Updated Phase 1 Data Validates the Feasibility of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma

(2021) Sham Mailankody et al.   BLOOD

Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy

(2021) Oliver Van Oekelen et al.   NATURE MEDICINE

CAR T and CAR NK cells in multiple myeloma: Expanding the targets

(2020) Urvi A. Shah et al.   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

Results from CARTITUDE-1: A Phase 1b/2 Study of JNJ-4528, a CAR-T Cell Therapy Directed Against B-Cell Maturation Antigen (BCMA), in Patients with Relapsed and/or Refractory Multiple Myeloma (R/R MM)

(2020) Deepu Madduri et al.   BLOOD

Selinexor, Pomalidomide, and Dexamethasone (SPd) in Patients with Relapsed or Refractory Multiple Myeloma

(2020) Christine I Chen et al.   BLOOD

Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors

(2020) Enli Liu et al.   NEW ENGLAND JOURNAL OF MEDICINE

CRISPR-engineered T cells in patients with refractory cancer

(2020) Edward A. Stadtmauer et al.   SCIENCE

Glypican-3–Specific CAR T Cells Coexpressing IL15 and IL21 Have Superior Expansion and Antitumor Activity against Hepatocellular Carcinoma

(2020) Sai Arun Batra et al.   Cancer Immunology Research

Recent progress in and challenges in cellular therapy using NK cells for hematological malignancies

(2020) Junji Tanaka et al.   BLOOD REVIEWS

Orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed/refractory multiple myeloma (RRMM): update of the phase 1/2 EVOLVE study (NCT03430011).

(2020) Sham Mailankody et al.   JOURNAL OF CLINICAL ONCOLOGY

Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma

(2020) Eugenia Zah et al.   Nature Communications

Deregulation of Adaptive T Cell Immunity in Multiple Myeloma: Insights Into Mechanisms and Therapeutic Opportunities

(2020) Noémie Leblay et al.   Frontiers in Oncology

Recent advances in CAR-T cell engineering

(2020) Ruihao Huang et al.   Journal of Hematology & Oncology

Broad Cytotoxic Targeting of Acute Myeloid Leukemia by Polyclonal Delta One T Cells

(2019) Biagio Di Lorenzo et al.   Cancer Immunology Research

Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy

(2019) Ujjawal H. Gandhi et al.   LEUKEMIA

B cell maturation antigen–specific CAR T cells are clinically active in multiple myeloma

(2019) Adam D. Cohen et al.   JOURNAL OF CLINICAL INVESTIGATION

Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma

(2019) Jie Xu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Universal Ready-to-Use Immunotherapeutic Approach for the Treatment of Cancer: Expanded and Activated Polyclonal γδ Memory T Cells

(2019) Vinicia A. Polito et al.   Frontiers in Immunology

The microenvironment in myeloma

(2019) Oliver C. Lomas et al.   CURRENT OPINION IN ONCOLOGY

Targeting REGNASE-1 programs long-lived effector T cells for cancer therapy

(2019) Jun Wei et al.   NATURE

Chimeric Antigen Receptor-Engineered Human Gamma Delta T Cells: Enhanced Cytotoxicity with Retention of Cross Presentation

(2018) Anna Capsomidis et al.   MOLECULAR THERAPY

Rewiring T-cell responses to soluble factors with chimeric antigen receptors

(2018) ZeNan L Chang et al.   Nature Chemical Biology

Improving the Efficiency of Vγ9Vδ2 T-Cell Immunotherapy in Cancer

(2018) Timm Hoeres et al.   Frontiers in Immunology

Gamma Delta T Cell Therapy for Cancer: It Is Good to be Local

(2018) C. David Pauza et al.   Frontiers in Immunology

A versatile system for rapid multiplex genome-edited CAR T cell generation

(2017) Jiangtao Ren et al.   Oncotarget

CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells

(2017) Levi J. Rupp et al.   Scientific Reports

Augmentation of Antitumor Immunity by Human and Mouse CAR T Cells Secreting IL-18

(2017) Biliang Hu et al.   Cell Reports

CRISPR-Cas9 mediated LAG-3 disruption in CAR-T cells

(2017) Yongping Zhang et al.   Frontiers of Medicine

A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors

(2016) Xiaojun Liu et al.   CANCER RESEARCH

TALEN-Mediated Inactivation of PD-1 in Tumor-Reactive Lymphocytes Promotes Intratumoral T-cell Persistence and Rejection of Established Tumors

(2016) Laurie Menger et al.   CANCER RESEARCH

Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits

(2016) Kole T. Roybal et al.   CELL

CRISPR-Cas9-mediated multiplex gene editing in CAR-T cells

(2016) Xiaojuan Liu et al.   CELL RESEARCH

Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients

(2016) Michael Ghermezi et al.   HAEMATOLOGICA

T cells in multiple myeloma display features of exhaustion and senescence at the tumor site

(2016) Claudia Zelle-Rieser et al.   Journal of Hematology & Oncology

Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients

(2016) Michael Ghermezi et al.   HAEMATOLOGICA

TRUCKs: the fourth generation of CARs

(2015) Markus Chmielewski et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Clinical overview of anti-CD19 BiTE® and ex vivo data from anti-CD33 BiTE® as examples for retargeting T cells in hematologic malignancies

(2015) Gerhard Zugmaier et al.   MOLECULAR IMMUNOLOGY

γ-secretase directly sheds the survival receptor BCMA from plasma cells

(2015) Sarah A. Laurent et al.   Nature Communications

T-cell Exhaustion in Multiple Myeloma Relapse after Autotransplant: Optimal Timing of Immunotherapy

(2015) D. J. Chung et al.   Cancer Immunology Research

Ex vivoexpanded human circulating Vδ1 γδT cells exhibit favorable therapeutic potential for colon cancer

(2015) Dang Wu et al.   OncoImmunology

Reversal of Tumor Immune Inhibition Using a Chimeric Cytokine Receptor

(2014) Ann M Leen et al.   MOLECULAR THERAPY

CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma

(2013) J Chu et al.   LEUKEMIA

PD-1- and CTLA-4-Based Inhibitory Chimeric Antigen Receptors (iCARs) Divert Off-Target Immunotherapy Responses

(2013) V. D. Fedorov et al.   Science Translational Medicine

Positive conversion of negative signaling of CTLA4 potentiates antitumor efficacy of adoptive T-cell therapy in murine tumor models

(2012) J. H. Shin et al.   BLOOD

Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival

(2012) Eric Sanchez et al.   BRITISH JOURNAL OF HAEMATOLOGY

Human Vdelta1 gamma-delta T cells exert potent specific cytotoxicity against primary multiple myeloma cells

(2012) Andrea Knight et al.   CYTOTHERAPY

Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells

(2012) Christopher C Kloss et al.   NATURE BIOTECHNOLOGY

Selective Expansion of Chimeric Antigen Receptor-targeted T-cells with Potent Effector Function using Interleukin-4

(2010) Scott Wilkie et al.   JOURNAL OF BIOLOGICAL CHEMISTRY